A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma

Table 2 Correlation of BRAF Mutation with clinico-pathological parameters in colorectal carcinoma

	Total		Positive		Negative		P value
	N	%	N	%	N	%	P value
Total number of cases	757		19	2.5	738	97.5
Age
< 50 years	246	32.5	3	1.2	243	98.8	0.0938
> 50 years	511	67.5	16	3.1	495	97.9
Sex
Male	394	52.0	11	2.8	383	97.2	0.6044
Female	363	48.0	8	2.2	355	97.8
Tumour site*
Left colon	600	83.0	10	1.7	590	98.3	0.0019
Right colon	123	17.0	9	7.3	114	92.7
Histological type
Adenocarcinoma	673	88.9	18	2.7	655	97.3	0.3673
Mucinous Carcinoma	84	11.1	1	1.2	83	98.8
Tumour stage*
I	88	12.2	4	4.6	84	95.4	0.6853
II	255	35.3	7	2.7	248	97.3
III	289	40.0	6	2.1	283	97.9
IV	90	12.5	2	2.2	88	97.8
Differentiation
Well	74	9.8	2	2.7	72	97.3	0.8887
Moderate	590	77.9	14	2.4	576	97.6
Poor	93	12.3	3	3.2	90	96.8
MSI-Molecular*
MSI-H	81	11.1	6	7.4	75	92.6	0.0144
MSI-S/L	651	88.9	13	2.0	638	98.0
*KRAS* Mutation*
Positive	216	28.7	2	0.9	214	99.1	0.0518
Negative	537	71.3	17	3.2	520	96.8
CIMP*
High	24	5.1	4	16.7	20	83.3	0.0017
Low & middle	444	94.9	8	1.8	436	98.2

*Data were not available (NA) for some cases for tumor site (NA = 34), Stage (NA = 35), MSI-Molecular (NA = 25), KRAS Mutation (NA = 4), and CIMP (NA = 289).

ISSN: 1476-4598